As Deere Plows New Ground In AI Innovation, Health Care Should Reap Lessons

Deere & Co’s AI innovations have drawn praise from experts who say their restructuring of work holds lessons for health care and other industries.

The Senate’s 3 Options In Affordable Care Act Fight

To settle the fight over the Affordable Care Act, the Senate can do nothing, broker a short term compromise or finally tackle the core problem: rising healthcare costs

Hopping Mad Over Drug Company Product Hopping

Pharmaceutical patent protection can be extended when drug companies bring newer products to market before their first patent expires

Anthropic announces Claude for Healthcare following OpenAI’s ChatGPT Health reveal

Anthropic’s Claude for Healthcare is unveiled about a week after OpenAI announced its ChatGPT Health product.

As Rivals Retreat, Alignment Healthcare’s Medicare Advantage Enrollment Jumps

Alignment Healthcare reported its Medicare Advantage enrollment soared 31% compared to last year as larger rivals have retreated from such coverage for older adults.

Why Pharmacies Like Walgreens, Rite Aid And Independents Are Dying

“Can you — should you — keep expanding at this pace?” “Yes, we can… and yes, we should…. We would be crazy not to.”

New Dietary Guidelines Promote Meat, Underplay Vegetarian Options

New U.S. dietary guidelines push meat and animal-based products while underplaying plant-based vegetarian options. More balanced public health messaging may be warranted.

Humana’s CenterWell Pharmacy Launches Employer Venture Using Lilly’s GLP-1 Drugs

Humana’s CenterWell pharmacy will dispense GLP-1 weight loss drugs made by Eli Lilly as part of a new program for employers to help their workers manage obesity.

Causes And Implications Of Discontinuing GLP-1 Weight Loss Drugs

Discontinuing obesity medicines means the weight comes back and people lose the cardiovascular and metabolic benefits conferred by the drugs.

A ‘Holy Grail’ Sleep Apnea Pill Could Be On The Market Next Year

Sleep apnea affects as many as 80 million in the U.S. Now Apnimed, the $400 million company behind the first ever pill to treat it, is preparing to file for FDA approval.